ArticleEuropean heart journal. Cardiovascular pharmacotherapy2020
Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Article in European heart journal. Cardiovascular pharmacotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Efficacy and safety of hydroxychloroquine as add-on therapy in uncontrolled type 2 diabetes patients who were using two oral antidiabetic drugs.Journal of endocrinological investigation · 2021Trial
- Hexapeptide-Liposome Nanosystem for the Delivery of Endosomal pH Modulator to Treat Acute Lung Injury.Journal of functional biomaterials · 2025Article
- Pharmacometric and Electrocardiographic Evaluation of Chloroquine and Azithromycin in Healthy Volunteers.Clinical pharmacology and therapeutics · 2022Article
- Long COVID-19 and Postural Orthostatic Tachycardia Syndrome- Is Dysautonomia to Be Blamed?Frontiers in cardiovascular medicine · 2022Review
- Cardiovascular Complications of COVID-19: Pharmacotherapy Perspective.Cardiovascular drugs and therapy · 2021Review
- Adverse Effects Associated With the Use of Antimalarials During The COVID-19 Pandemic in a Tertiary Care Center in Mexico City.Frontiers in pharmacology · 2021Article
- Chloroquine, hydroxychloroquine, and COVID-19: Systematic review and narrative synthesis of efficacy and safety.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2020Article
- COVID-19: Current Developments and Further Opportunities in Drug Delivery and Therapeutics.Pharmaceutics · 2020Review
- How to overcome cardiovascular challenges in COVID-19 patients: a guide for common practice.Acta bio-medica : Atenei Parmensis · 2020Review
- Article
- Emerging Prevention and Treatment Strategies to Control COVID-19.Pathogens (Basel, Switzerland) · 2020Review
- Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.Frontiers in pharmacology · 2020Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.